News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally.

Tags: OvarianCancer, TargetedTherapy

  • Erica Mayer, MD, MPH, and colleagues are leading a pilot phase 2 clinical trial to test the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer.

Tags: BreastCancer, TargetedTherapy

  • F. Stephen Hodi, MD, and colleagues report the immunotherapy drug nivolumab continues to show long-term effectiveness in treating metastatic melanoma, achieving a three-year survival rate of 41 percent against the deadly skin cancer.

Tags: Melanoma, Immunotherapy

  • Results from a study evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.

Tags: BreastCancer, TargetedTherapy

  • According to new research, a technique for reading the genetic abnormalities in patient tumors with a simple blood test has passed a critical test of accuracy and reliability.

Tags: BasicResearch

  • New research shows patients with non-metastatic ovarian cancer live longer when chemotherapy is delivered into the abdomen instead of by standard intravenous infusion, yet only a minority of eligible patients are receiving it.

Tags: OvarianCancer

  • A new study shows about half of non-small cell lung cancer (NSCLC) patients whose tumors no longer responded to conventional targeted drugs had their tumors shrink after receiving a new, more precisely targeted agent.

Tags: EGFR, LungCancer

  • Dana-Farber researchers report new data point to the lasting benefit, for many patients, of the targeted drug imatinib which has revolutionized the treatment of advanced gastrointestinal stromal tumors.

Tags: Sarcoma, TargetedTherapy

  • Ursula Matulonis, MD, and colleagues report a two-drug combination that disrupts critical signaling circuits in cancer cells has produced an observable benefit in patients with recurrent high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

Tags: BreastCancer, CervicalCancer

  • One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure (CHF) finds improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit.

Tags: ChildhoodCancer, Survivorship

Showing 21-30 of 518 items